New Therapies for Neuropsychiatric Disorders

Amorsa, in collaboration with its partners, has selected its lead clinical candidate with treatment-resistant depression as the initial target indication. To date we have completed over 50 de-risking in vitro and in vivo preclinical studies with multiple, well-defined compounds, all based on ketamine’s deuterated active metabolites, deuterated (R)- and (S)- norketamine. We are in the process of evaluating other related indications including PTSD and obsessive-compulsive disorder.